FDA Drug Info Rounds Video
Welcome to Drug Info Rounds, a series of training videos for practicing clinical and community pharmacists. Drug Info Rounds is brought to you by pharmacists in the FDA’s Center for Drug Evaluation and Research (CDER), Office of Communications (OCOMM), Division of Drug Information (DDI). Pharmacists in DDI answer hundreds of questions everyday about drug products and FDA actions. Our goal is to provide important and timely drug information to pharmacists so they can help patients make better medication decisions.
- Expanded Access (October 2014)
FDA Drug Info Rounds pharmacists discuss expanded access to investigational drugs.
- Traveling with Prescription Medications (August 2014)
FDA Drug Info Rounds pharmacists discuss key points pharmacists should counsel their patients on prior to travel.
- Managing Drug Shortages (July 2014)
FDA Drug Info Rounds pharmacists discuss the management of drug shortages and how the FDA’s role has changed in recent years.
- Electronic Orange Book (March 2014)
FDA Drug Info Rounds pharmacists discuss how to search the Electronic Orange Book for generic equivalents, patents, and exclusivity.
- Drug Promotion (October 2013)
FDA Drug Info Rounds pharmacists discuss the many elements surrounding the marketing and advertising of a prescription drug product.
- Drug Name Review (September 2013)
FDA Drug Info Rounds pharmacists discuss FDA’s responsibility for reviewing and approving new product names.
- Communicating Benefit and Risk Information (August 2013)
FDA Drug Info Rounds pharmacists talk about the benefit risk balance, and how health care professionals may approach this topic with their patients.
- Drug Safety Communications (November 2012)
FDA Drug Info Rounds pharmacists discuss how Drug Safety Communications let health care providers, patients, and consumers know about newly observed potential risks of FDA-approved drugs.
- Distribution of Medication Guides (October 2012)
FDA Drug Info Rounds pharmacists discuss the requirements for providing Medication Guides.
- Medication Errors (September 2012)
FDA Drug Info Rounds pharmacists discuss Medication Errors and how FDA educates the public about medication error prevention through public health advisories, medication guides and outreach partnerships with other organizations.
- Patents and Exclusivity (August 2012)
FDA Drug Info Rounds pharmacists discuss Patents and Exclusivity and how they work in a similar fashion but are distinctly different from one another.
- Accelerated Approval Program (July 2012)
FDA Drug Info Rounds pharmacists discuss the Accelerated Approval Program and how FDA helps make new, potentially lifesaving drugs available more quickly.
- Communicating Drug Safety Messages (April 20, 2011)
FDA Drug Info Rounds pharmacists discuss the vital role that pharmacists play in assisting the FDA with communicating drug safety messages.
- Drug Shortages (December 1, 2010)
FDA Drug Info Rounds pharmacists discuss FDA's role in responding to and mitigating drug shortages.
- Evamist (September 30, 2010)
FDA Drug Info Rounds pharmacists discuss FDA's ongoing safety review of adverse event reports in children who may have been unintentionally exposed to the drug through skin contact with women using Evamist.
- Proton Pump Inhibitors (PPIs) (August 9, 2010)
FDA Drug Info Rounds pharmacists discuss new safety information about a possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors, strengths and limitations of the studies, and recommendations for pharmacists.
- Long-Acting Beta-Agonists (LABAs) (July 16, 2010)
FDA Drug Info Rounds pharmacists discuss the new recommendations in the drug labels of Long-Acting Beta-Agonists (LABAs), and provide ways pharmacists can help patients use LABAs safely in the treatment of asthma.
- Single-ingredient Oral Colchicine (May 14, 2010)
FDA Drug Info Rounds pharmacists discuss the differences between approved and unapproved colchicine products, concerns regarding unapproved single-ingredient oral colchicine, and how patients can offset the increased cost of Colcrys.